-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | Sunshine
On July 6, CMS released an announcement announcing that the application for registration and marketing authorization of diazepam nasal spray has been accepted by the State Food and Drug Administration
It is estimated that there are about 6 million patients with active epilepsy in China, and there are about 400,000 new epilepsy patients every year
The product was developed by Neurelis, and CMS reached a cooperation with Neurelis in 2018 and introduced the product
Compared with intravenous diazepam, PK studies in healthy subjects showed that it has an absolute bioavailability of 96% and a bioavailability equivalent to that of diazepam rectal gel, while the variability is significantly reduced; epilepsy The PK study in patients showed similar exposure in seizure or non-seizure state and strong correlation with the pharmacokinetic results of healthy subjects; 12-month open label long-term safety of repeated medication in epilepsy patients Phase III clinical studies have shown that it has extraordinary tolerability and safety when repeated at home during epileptic seizures
PharmaGo shows that diazepam nasal spray is also the only and first product developed in the form of a spray in the development of domestic enterprises
Original title: The first application for the marketing of diazepam nasal spray was accepted